| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5c24684033fba97d1ad845ce453a57e3 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-18 |
| filingDate |
1995-01-17^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
1997-01-28^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a552fe5fa231c0ebe00bf592599fdf4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e508e766f6ef0ebe2ae9d50fdac8b5e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe54c319451545df50b59ccc4492ca35
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be32573a0e64b02aaa2c9990057242f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_947ca37acddaed8b0d45052234d87e8c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7386f2a074744e5d593b387e14afe6b6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c187050e952d66c07bd2be64a57bfa72 |
| publicationDate |
1997-01-28^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-5597803-A |
| titleOfInvention |
Bradykinin peptides with modifications at the N terminus |
| abstract |
Peptides of the formula I Z-P-A-B-C-E-F-K-(D)Q-G-M-F'-I(I) and the physiologically tolerated salts thereof, are described. They have an excellent bradykinin-antagonistic action. They are obtained by reacting reacting a fragment with a C-terminal free carboxyl group or its activated derivative with a corresponding fragment with an N-terminal free amino group or assembling the peptide stepwise, where appropriate eliminating in the compound obtained in this way one or more protective groups introduced temporarily to protect other functionalities, and where appropriate converting the compounds of the formula I obtained in this way into the physiologically tolerated salt thereof. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2004248809-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7105172-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5863901-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6479515-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6699486-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019202057-A1 |
| priorityDate |
1992-04-04^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |